Esperion Therapeutics Inc

Financials

Cash from operating activities -85.18 M-263.81 M-174.83 M-135.49 M-23.65 M-13.09 M -13.09 M Cash from investing activities 21.36 M-50.48 M8.1 M42.5 M-317 K0 0 Cash from financing activities 201.72 M268.22 M32.61 M50.46 M86.48 M36.18 M 36.18 M Free cash flow -86.05 M-263.81 M-174.83 M-135.49 M-23.97 M-13.09 M -13.09 M

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

ESPR

Financials

Esperion Therapeutics Inc

Nouvelles

Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?

Esperion vend ses droits de redevances au Japon pour 50 millions de dollars à Athyrium

Esperion : l’acide bempédoïque réduit le risque d’AVC de 22%

Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?

BofA réitère sa note Sous-performance sur Esperion Therapeutics

BofA reiterates Esperion Therapeutics stock Underperform rating

L’acide bempédoïque obtient des recommandations de haut niveau pour le cholestérol

Bempedoic acid gains top-level guideline recommendations for cholesterol

Citizens relève l’objectif de cours d’Esperion Therapeutics sur fond de croissance des médicaments

Citizens raises Esperion Therapeutics price target on drug growth

ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down

H.C. Wainwright réitère sa recommandation d’achat sur Esperion, objectif 16$